CT Financial Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

CT Financial Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$572K	Buy	16,629 +3,178	+24%	+$112K	0.35%	77
2016 Q4	$388K	Buy	13,451 +4,795	+55%	+$127K	0.25%	93
2016 Q3	$275K	Sell	8,656 -1,000	-10%	-$33.9K	0.17%	119
2016 Q2	$313K	Buy	9,656 +2,505	+35%	+$83.8K	0.19%	104
2016 Q1	$200K	Buy	7,151 +4,851	+211%	+$106K	0.11%	152
2015 Q4	$82K	Hold	2,300	–	–	0.05%	234
2015 Q3	$76.1K	Hold	2,300	–	–	0.05%	243
2015 Q2	$96.3K	Buy	2,300 +1,300	+130%	+$50.3K	0.05%	225
2015 Q1	$32.6K	Buy	1,000 +600	+150%	+$20.6K	0.02%	345
2014 Q4	$12.7K	Buy	+400	New	+$11.3K	0.01%	356
2014 Q1	$32.6K	Buy	+1,000	New	+$25.3K	0.02%	345

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

CT Financial Advisors's ACAD Position: Q1 2017 in Review

CT Financial Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 24% in Q1 2017, buying an estimated $112K and bringing the position to 16,629 shares worth $572K. The position accounts for 0.35% of the portfolio, ranked #77.

CT Financial Advisors first reported a position in ACAD in Q1 2014 and has held it in 11 quarters since. 219 funds tracked by Wall St. Rank hold ACAD as of Q1 2017.

CT Financial Advisors held 16,629 shares of Acadia Pharmaceuticals worth $572K as of Q1 2017.
CT Financial Advisors bought 3,178 Acadia Pharmaceuticals shares in Q1 2017, an estimated $112K.
Acadia Pharmaceuticals made up 0.35% of CT Financial Advisors's portfolio in Q1 2017, its #77 holding.
CT Financial Advisors first reported a position in Acadia Pharmaceuticals in Q1 2014 and has held it in 11 quarters since.
219 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2017.

Based on CT Financial Advisors's 13F filing for Q1 2017, filed 7 Apr 2017.